PMID- 35537231
OWN - NLM
STAT- MEDLINE
DCOM- 20220616
LR  - 20220616
IS  - 1532-818X (Electronic)
IS  - 0196-0709 (Linking)
VI  - 43
IP  - 4
DP  - 2022 Jul-Aug
TI  - Association of immune response with overall and disease-free survival in 
      laryngeal squamous cell carcinomas.
PG  - 103477
LID - S0196-0709(22)00104-1 [pii]
LID - 10.1016/j.amjoto.2022.103477 [doi]
AB  - OBJECTIVES: This study aimed to examine the relationship between checkpoint 
      receptors (PD-1, PD-L1, PD-L2, CTLA-4) and lymphoid infiltration level (TILs) 
      with prognostic features of patients with laryngeal squamous cell carcinoma 
      (LSCC). METHODS: A retrospective study was designed at a tertiary referential 
      university hospital between April 2008 and December 2020. The surgical specimen 
      of the patients who met the eligibility criteria were re-examined 
      histopathological, sociodemographic, clinical, pathological, and follow-up 
      findings of patients were determined. The impact of PD-1, PD-L1, PD-L2, CTLA4, 
      and TILs levels for the presence of cancer recurrence, disease-specific 
      mortality, overall survival (OS), disease-free survival (DFS) was investigated. 
      RESULTS: Forty-five patients with LSCC were included in the study. The mean 
      follow-up period was 48.3 +/- 14.3 months (min: 36, max 84). TILs scores were 
      detected significantly lower in patients with distant metastasis and recurrence 
      (p = 0.046 and 0.010). Also, only TILs was a significant risk factor for 
      recurrence and survival among the PD-1, PD-L1, PD-L2, CTLA-4, and TILs 
      (HR = 0.217 CI: 0.070-0.679, p = 0.009 and HR = 0.566, CI: 0,321-980, p = 0.048). 
      Similarly, for the TILs score: > 1 was significant for DFS. (Long-Rank = 0.009). 
      The examined markers and TILs scores were not a significant predictive factor for 
      OS. CONCLUSION: An increase in TILs density in LSCCs is associated with a better 
      prognosis. However, PD-1, PD-L1, PD-L2, CTLA-4 could not be associated with 
      prognosis. Controlled studies combined with immunotherapy treatment results are 
      needed to reveal their role as a marker and prognostic factor of the anti-tumor 
      immune response.
CI  - Copyright (c) 2022 Elsevier Inc. All rights reserved.
FAU - Bayrak, Asuman Feda
AU  - Bayrak AF
AD  - Department of Otorhinolaryngology, Katip Celebi University Ataturk Teaching and 
      Research Hospital, Izmir, Turkey. Electronic address: fedabayrak@gmail.com.
FAU - Eliyatkin, Nuket Ozkavruk
AU  - Eliyatkin NO
AD  - Department of Pathology, Katip Celebi University Ataturk Teaching and Research 
      Hospital, Izmir, Turkey.
FAU - Islek, Akif
AU  - Islek A
AD  - Department of Otorhinolaryngology, Acibadem Eskisehir Hospital, Eskisehir, 
      Turkey.
FAU - Ozkul, Yilmaz
AU  - Ozkul Y
AD  - Department of Otorhinolaryngology, Katip Celebi University Ataturk Teaching and 
      Research Hospital, Izmir, Turkey.
FAU - Kilic, Hacer Sena
AU  - Kilic HS
AD  - Department of Pathology, Katip Celebi University Ataturk Teaching and Research 
      Hospital, Izmir, Turkey.
FAU - Aktas, Safiye
AU  - Aktas S
AD  - Department of Basic Oncology, Dokuz Eylul University Institute of Oncology, 
      Izmir, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20220504
PL  - United States
TA  - Am J Otolaryngol
JT  - American journal of otolaryngology
JID - 8000029
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CTLA-4 Antigen)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
MH  - *B7-H1 Antigen
MH  - Biomarkers, Tumor
MH  - CTLA-4 Antigen
MH  - Disease-Free Survival
MH  - *Head and Neck Neoplasms/pathology
MH  - Humans
MH  - Immunity
MH  - Lymphocytes, Tumor-Infiltrating/pathology
MH  - Neoplasm Recurrence, Local/pathology
MH  - Prognosis
MH  - Programmed Cell Death 1 Receptor
MH  - Retrospective Studies
MH  - Squamous Cell Carcinoma of Head and Neck/pathology
OTO - NOTNLM
OT  - Cancer immunotherapy
OT  - Laryngeal carcinoma
OT  - PD-L1
OT  - Survival
OT  - TILs
EDAT- 2022/05/11 06:00
MHDA- 2022/06/18 06:00
CRDT- 2022/05/10 18:13
PHST- 2022/03/03 00:00 [received]
PHST- 2022/04/20 00:00 [revised]
PHST- 2022/05/01 00:00 [accepted]
PHST- 2022/05/11 06:00 [pubmed]
PHST- 2022/06/18 06:00 [medline]
PHST- 2022/05/10 18:13 [entrez]
AID - S0196-0709(22)00104-1 [pii]
AID - 10.1016/j.amjoto.2022.103477 [doi]
PST - ppublish
SO  - Am J Otolaryngol. 2022 Jul-Aug;43(4):103477. doi: 10.1016/j.amjoto.2022.103477. 
      Epub 2022 May 4.